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Abstract
Background: The objective of this study was to describe the clinical and molecular features of the
first South African family with X-linked hyper-IgM syndrome (HIGM1).
Methods: Diagnoses were based on immunoglobulin results and the absence of CD40 ligand
(CD40L) expression on activated T-cells. Complete molecular characterisation involved CD40L
cDNA sequencing, and genomic DNA analysis by polymerase chain reaction amplification,
restriction enzyme digestion and sequencing. A PCR-based diagnostic assay was established for
carrier detection and prenatal diagnosis in this family.
Results: There were originally six children, three males and three females. The eldest boy died
after being diagnosed with hypogammaglobulinaemia, before HIGM1 was considered. This disorder
was diagnosed in the second eldest boy at the age of 5 years, after failing to detect CD40L
expression on his activated T-cells. A deficiency of CD40L was also confirmed in the youngest male
at the age of 5 years. Both younger brothers have since died of infections relating to HIGM1.
Molecular investigation showed that exon 3 was deleted from the CD40L mRNA of the affected
males. Genomic DNA analysis identified a 1.5 kilobase deletion, spanning exon 3 and including
extended flanking intronic sequence. Carrier status in the mother was confirmed by RT-PCR of her
CD40L mRNA. Genetic analysis of the three female children was deferred because they were
below the legal consenting age of 18 years. A PCR-based assay for genomic DNA was established
for easy identification of female carriers and affected males in the future.
Conclusions: This study confirmed the diagnosis of HIGM1 in the first South African family to be
investigated and identified a novel mutation in the CD40L gene.
Background
Immunodeficiency with hyper-IgM was first described in
1960 [1] and mapped to Xq26, in 1992, using DNA from
families showing X-linked inheritance of the condition
[2]. This locus was known to contain the CD40 ligand
(CD154) gene. Shortly thereafter, several groups inde-
pendently showed that mutations in this gene caused the
disorder, which is now known as Hyper IgM Type I
(HIGM1) [3,4]. The autosomal recessive forms took
longer to delineate with two defects being described in the
past three years. Hyper IgM Type II (HIGM2) is caused by
mutations in the activation-induced cytidine deaminase
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(AID) gene, while Type III (HIGM3) is due to defects in
the gene encoding CD40 [5,6].
The clinical manifestations of HIGM1 include recurrent
upper and lower respiratory tract infection, interstitial
pneumonia, chronic diarrhoea, oral ulcers, sclerosing
cholangitis and hepatitis. Less commonly arthritis,
meningoencephalitis and tumours occur [7,8]. Patients
with HIGM1 are uniquely susceptible to interstitial pneu-
monia caused by Pneumocyctis carinii. Cryptosporidium par-
vum  is frequently isolated from patients with chronic
diarrhoea and ascending cholangitis. The immunodefi-
ciency classically presents with elevated or normal IgM
levels and low IgA, IgG and IgE concentrations. Neutro-
paenia is frequently documented. Treatment consists of
prophylactic co-trimoxazole and intranvenous immu-
noglobulin replacement, and advice to boil water to pre-
vent cryptosporidium infection. Granulocyte-colony
stimulating factor may improve the neutropaenia. Despite
optimal medical treatment prognosis is unfavourable as
less than 30% survive beyond the 3rd decade of life. Bone
marrow transplantation may be curative and is being
increasingly considered Patients with advanced liver dis-
ease occasionally benefit from combined liver and bone
marrow transplantation [9,10].
The CD40L gene comprises 5 exons, 4 introns, and spans
12 kilobases. It encodes a type II transmembrane glyco-
protein of 261 amino acids, which has a molecular mass
of 39 kDa and is a member of the TNF superfamily.
Domains of the protein include a short cytoplasmic tail, a
transmembrane section and an extracellular region that
shares homology with TNF-α. CD40L is mainly expressed
by activated CD4+ T-cells [4,11,12] and is functional as a
homotrimer. Other cells expressing CD40L include B
cells, macrophages, monocytes, dendritic cells and
endothelial cells. The interaction of CD40L on activated
CD4 cells with CD40 on B-cells induces B-cell prolifera-
tion, immunoglobulin isotype switching, germinal centre
formation and somatic hypermutation. Dysfunctional
CD40 ligation thus prevents isotype switching from IgM,
and results in the typical immunodeficiency [12,13]. Fail-
ure to isotype switch, as well as failure to activate Kuppfer
cells and pulmonary macrophages increases the risk for
Pneumocystis carinii and Cryptosporidial infection [7].
Autosomal forms of hyper-IgM syndrome are due to
defects of B-cells, rather than T-cells [14].
The European CD40L defect database contains mutations
scattered throughout the length of the gene. However,
mutations are more common in the extracellularly located
TNF-homology domain [15]. A variety of missense, non-
sense, splice-site, deletion and insertion mutations have
been reported [15,16]. In the present report we describe
the characterisation of a novel deletion mutation in the
first South African kindred with HIGM1.
Methods
Subjects
The kindred is of African ancestry and included 6 children,
3 boys and 3 girls. All three boys were affected and all died
during early childhood from complications relating to
hyper-IgM syndrome (Figure 1). The Research Ethics
Committee of the University of Cape Town approved this
study. Informed consent for molecular analysis was
obtained from the parents.
CD40L expression
CD40L expression on activated T cells was measured by
flow cytometry as previously described [17].
Activation of T-cells and CD40L cDNA analysis
Peripheral blood mononuclear cells (PBMCs) (10 × 106)
separated from heparinized blood by Ficoll isopaque den-
sity centrifugation, were incubated in 10 ml RPMI-1640
cell culture medium, 12% AB serum, with phorbol myr-
istate acetate (PMA) (10 000 ng/ml) and Ionomycin (1.5
mg/ml) for 6 hours, to allow for activation of the T-cells.
Total RNA was isolated and the mRNA fraction converted
into cDNA, from which CD40L cDNA was amplified
using CD40L specific primers. The primer pair used was:
5'-CTCTGCCAGAAGATACCATTTCAAC-3' (F) and 5'-
TATGAAGACTCCCAGCGTCAGC-3' (R). The amplified
cDNA was sequenced using the ABI BigDye sequencing
method.
Results
Clinical and laboratory data
The clinical data of the three affected children are summa-
rised in table 1. Neutropaenia was intermittently
Pedigree of the affected family Figure 1
Pedigree of the affected family.
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documented during the clinical course of the two younger
affected males but was not documented in the eldest
male. There was no CD40L expressed by the activated T
cells of two of the affected boys (data not shown).
Nucleic acid analysis
CD40L cDNA was analysed in the first instance, with RT-
PCR yielding a PCR product from the proband (second
eldest, affected male, which was approximately 60 bp
shorter than normal (Figure 2a). This was most likely
indicative of a splicing deletion involving either exon 3 or
4 as they are of this magnitude. Sequencing confirmed a
deletion of exon 3 (58 bp), with exon 2 correctly spliced
to exon 4 (Figure 2a,2b).
Attempts to examine exon 3 splice-site sequences were
unsuccessful as we were unable to amplify exon 3 from
genomic DNA using close, flanking intronic PCR primers.
This problem was suggestive of a large deletion
incorporating exon 3 and some flanking intronic
sequence. Knowing that the patient had an intact exon 2
and 4 we chose primers with sequence from the intronic
regions immediately flanking these exons. We were able
to amplify across these exons by using long range Taq
polymerase (Expand TM High Fidelity PCR System,
[Roche, Catalogue No 1732641]). This gave PCR products
of 6059 bp from a normal male and approximately 4500
bp from our patient, indicative of a deletion approximat-
ing 1500 bp. The positions of the deletion breakpoints in
introns 2 and 3 were roughly determined by comparison
of the restriction maps of both PCR products. Localisation
of these breakpoints, allowed us to sequence across the
junction site in one sequencing attempt and size the dele-
tion at exactly 1500 bp. This site and immediate flanking
sequence is given in Figure 3a.
To facilitate carrier detection we set up a PCR assay using
primers flanking the deleted region. This assay gives a PCR
product of 1741 bp from normal alleles and a product of
241 bp from the mutant allele. This is clearly shown in
Figure 3b where PCR products from the patient and his
carrier mother have been compared.
This deletion mutation is novel and has been submitted to
the CD40L database with the following annotation: Refer-
ence sequence NT_011719, variant sequence bases
3083058–3084557 deleted [15].
Discussion
In sub-Saharan Africa the diagnosis of primary immuno-
deficiency diseases is constrained by limited diagnostic
facilities; few African centres have reported on these con-
ditions. This manuscript is the first South African report of
a kindred with HIGM1 to be fully characterised at the clin-
ical and molecular level. While the immunology service at
Red Cross Children's Hospital has been diagnosing pri-
mary immunodeficiency diseases for more than 30 years
[18] a flow cytometric assay [17] for detecting CD40 lig-
and expression on activated T-cells was only established
in 1998, facilitating the diagnosis of HIGM1 in the index
family. This development occurred after the eldest,
affected boy had died.
Low IgG concentration with either a normal or increased
IgM concentration was present at the initial assessment of
all three patients and is a fairly consistent feature of
HIGM1 [7]. However, the normal IgA concentration
recorded in two of the affected males is not a usual feature,
and it should not thus preclude consideration of HIGM1
in the differential diagnosis of males with hypogamma-
globulinaemia. Although the second patient initially had
a normal IgM concentration, 3 years later the IgM concen-
tration was 1.5 times the normal upper limit. The elevated
IgM concentration in these patients is not a genetically
determined feature but rather reflects a chronic, poorly
controlled primary response to the many infections that
Table 1: Clinical data
Patient No. Age at investigation Immunoglobulin levels 
(initial)
CD40L status Treatment and Outcome
1 10 months IgM ↑, IgG ↓, IgA normal Not done 4-weekly IVIG administered. Developed 
bronchiectasis. Died at age 17 months during an 
episode of pneumonia and acute-on-chronic 
respiratory failure
2 24 months IgM normal, IgG ↓, IgA ↓ CD40L deficiency 4-weekly IVIG and cotrimoxazole prophylaxis 
administered. Developed cryptococcal-associated 
ascending cholangitis / chronic liver disease. Died 
at the age of 7 years of an unknown cause
3 9 months IgM ↑, IgG ↓, IgA normal CD40L deficiency 1 infusion of IVIG administered. Died at age 10 
months due to interstitial pneumonia and acute 
respiratory failureBMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/12
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afflict these patients [7]. Medical treatment did not pre-
vent the early demise of the three children. Despite intra-
venous immunoglobulin therapy less that 30% of patients
with HIGM1 live beyond the third decade as they also
have an increased tendency to autoimmune disease and
cancer [8,19]. Improved outcome of bone marrow trans-
plantation makes this therapeutic modality increasingly
attractive in treating children with HIGM1 [9,20].
The deletion of exon 3 from the CD40L gene not only
results in the loss of 19 amino acids from the primary
sequence but also alters the reading frame of the mRNA
transcript beyond the exon2 / exon 4 coupling (Figure 2a),
resulting in a premature termination codon 12 amino
acid residues downstream. The final mRNA transcript is
therefore shorter and carries a premature termination
codon within the first third of the prescribed coding
sequence. The introduction of premature stop codons in
mRNA transcripts is known to often hasten their degrada-
tion in a process referred to as nonsense-mediated mRNA
decay [21] and appears to be operative for this mutation.
The amplification of CD40L cDNA from the carrier
mother of our patient, clearly shows a marked reduction
in staining intensity for the shorter and mutated transcript
(Figure 2b) and is suggestive of a large discrepancy in
PBMC template concentrations of the mRNA transcripts
from the two alleles she carries.
Scrutiny of the CD40L mutation database reveals that
large deletions are rarely encountered in affected subjects,
showing the absence of repeat unit "hotspots" sometimes
recorded at other gene loci [22]. We have analysed the
breakpoint and flanking sequences from our patient and
find that the deletion has occurred at a short 4 bp direct
repeat (GGCC), which is similar to the short direct repeats
reported in deletions of the retinoblastoma gene [23].
Carrier detection in this family has only been extended to
the mother of our patient where PCR confirmed her obli-
gate carrier status (Figure 3b). This family has been coun-
selled to delay screening of the three female siblings until
they are older and are contemplating having children of
their own.
In conclusion, advances in the fields of genetics, and cel-
lular and molecular biology during the last decade have
helped to clarify many aspects of the pathogenesis of the
hyper IgM syndromes, and allowed us to completely char-
(a) Polyacrylamide gel electrophoresis of PCR amplified CD40L cDNA from a normal control (lane 2), the proband (II.5; lane  3), and his mother (lane 4), MWT markers (lanes 1 and 5); (b) Boundary sequences of exons 2, 3 and 4 of control and patient  CD40L cDNA Figure 2
(a) Polyacrylamide gel electrophoresis of PCR amplified CD40L cDNA from a normal control (lane 2), the proband (II.5; lane 
3), and his mother (lane 4), MWT markers (lanes 1 and 5); (b) Boundary sequences of exons 2, 3 and 4 of control and patient 
CD40L cDNA. The sequence for exon 3 is shown in italics.
Exon 2               Exon 3                Exon 4
Normal: TTT GTG AAG GAT-------AAA G GT GAT CAG
Patient: TTT GTG AAG GTG ATC AGA
879 bp
821 bp
1     2      3      4      5   BMC Pediatrics 2003, 3 http://www.biomedcentral.com/1471-2431/3/12
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acterise the HIGM1 mutation in this family. Recent
progress should lead to a greater understanding of the
spectrum of immunological and genetic disorders in sub-
Saharan Africa.
List of abbreviations
cDNA complementary deoxyribonucleic acid
CD40L CD40 ligand
DNA deoxyribonucleic acid
HIGM1 X-linked hyper IgM syndrome or Hyper IgM Type
I
HIGM2 Hyper IgM Type II
HIGM3 Hyper IgM Type III
IgA Immunoglobulin A
IgE Immunoglobulin E
IgG Immunoglobulin G
IgM Immunoglobulin M
mRNA messenger ribonucleic acid
PCR polymerase chain reaction
RT-PCR reverse transcriptase polymerase chain reaction
TNF tumor necrosis factor
TNF-α tumor necrosis factor-α
PBMCs peripheral blood mononuclear cells
PMA phorbol myristate acetate
(a) Partial sequence across the deletion breakpoints in control DNA as compared to the sequence across the junction site in  our patient (Figure 1; II.5) Figure 3
(a) Partial sequence across the deletion breakpoints in control DNA as compared to the sequence across the junction site in 
our patient (Figure 1; II.5). Sequence corresponding to the beginning and end of the deleted section is given in italics. The short 
4 bp repeat at the breakpoints is underlined. (b) Agarose gel electrophoresis of PCR product spanning the 1500 bp deletion: 
MWT marker (lane 1), control DNA (lane 2), patient DNA (lane 3), maternal [carrier] DNA (lane 4).
                          Intron 2 Intron 3
Normal TGAGCTG  GGCCTA--------CACAGT GGCCGGTGG
Patient TGAGCTG  GGCCGGTGG
Exon3
1500b
1     2      3     4 
1741bp
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